Literature DB >> 8097794

Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells.

N M Hoosein1, C J Logothetis, L W Chung.   

Abstract

The effects of bombesin, vasoactive intestinal polypeptide (VIP), and a somatostatin analog (RC-160) on the in vitro invasion of reconstituted basement membrane (Matrigel) by two human prostatic carcinoma cell lines were examined. Aggressively growing PC-3 cells were found to be invasive in this assay in contrast to the relatively indolent LNCaP cells. Bombesin increased penetration of basement membrane by both cell lines. Although VIP had no effect on invasion by PC-3 cells, it enhanced invasion by LNCaP cells in a dose-dependent manner. In agreement with these results, VIP stimulated adenylate cyclase activity only in LNCaP cells. In contrast to bombesin and VIP, RC-160 did not alter invasion by either cell line. Our results suggest that certain neuroendocrine peptides can increase the invasive potential of prostatic carcinoma cells and may thereby contribute to the rapid progression and aggressive clinical course of prostate tumors containing neuroendocrine elements.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8097794     DOI: 10.1016/s0022-5347(17)36349-8

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  16 in total

1.  Development of a microplate assay for serum chromogranin A (CgA): establishment of normal reference values and detection of elevated CgA in malignant diseases.

Authors:  T L Wu; C P Chang; K C Tsao; C F Sun; J T Wu
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

2.  Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase.

Authors:  L F Lee; J Guan; Y Qiu; H J Kung
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

3.  Serum chromogranin A: early detection of hormonal resistance in prostate cancer patients.

Authors:  J T Wu; M E Astill; G H Liu; R A Stephenson
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

4.  Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer.

Authors:  Jiaoti Huang; Jorge L Yao; Li Zhang; Patricia A Bourne; Andrew M Quinn; P Anthony di Sant'Agnese; Jay E Reeder
Journal:  Am J Pathol       Date:  2005-06       Impact factor: 4.307

Review 5.  Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors.

Authors:  Lucia Baratto; Hossein Jadvar; Andrei Iagaru
Journal:  Mol Imaging Biol       Date:  2018-08       Impact factor: 3.488

6.  A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49.

Authors:  Lawrence D True; Kent Buhler; Janna Quinn; Emily Williams; Peter S Nelson; Nigel Clegg; Jill A Macoska; Thomas Norwood; Alvin Liu; William Ellis; Paul Lange; Robert Vessella
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

Review 7.  Neuroendocrine peptides in the prostate.

Authors:  P J Gkonos; A Krongrad; B A Roos
Journal:  Urol Res       Date:  1995

8.  Neuroendocrine differentiation in prostate cancer.

Authors:  Yin Sun; Junyang Niu; Jiaoti Huang
Journal:  Am J Transl Res       Date:  2009-02-05       Impact factor: 4.060

9.  Immunohistochemical detection of gastrin releasing peptide in patients with prostate cancer.

Authors:  Constantinos Constantinides; Andreas C Lazaris; Konstantinos N Haritopoulos; Dimitrios Pantazopoulos; Michalis Chrisofos; Aris Giannopoulos
Journal:  World J Urol       Date:  2003-07-05       Impact factor: 4.226

10.  Gastrin-releasing peptide receptor (GRPr) promotes EMT, growth, and invasion in canine prostate cancer.

Authors:  Said M Elshafae; Bardes B Hassan; Wachiraphan Supsavhad; Wessel P Dirksen; Rachael Y Camiener; Haiming Ding; Michael F Tweedle; Thomas J Rosol
Journal:  Prostate       Date:  2016-03-04       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.